AHU377 CRYSTAL FORM, PREPARATION METHOD AND USE THEREOF

(19)

(11)

EP 3 272 734 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	published in accordance with Art. 153(4) EPC

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	11.04.2018 Bulletin 2018/15

(43)	Date of publication:
	24.01.2018 Bulletin 2018/04

(21)	Application number: 16767714.5

(22)	Date of filing: 18.03.2016

(51)

International Patent Classification (IPC):

C07C 233/47^(2006.01)
C07D 257/04^(2006.01)

C07C 231/24^(2006.01)
A61P 9/04^(2006.01)

(86)	International application number:
	PCT/CN2016/076660

(87)	International publication number:
	WO 2016/150337 (29.09.2016 Gazette 2016/39)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	MA MD

(30)

Priority:

20.03.2015 CN 201510124555

(71)	Applicant: Crystal Pharmatech Co., Ltd.
	Suzhou, Jiangsu 215123 (CN)

(72)	Inventors:
	CHEN, Minhua Suzhou Jiangsu 215123 (CN) ZHANG, Yanfeng Suzhou Jiangsu 215123 (CN) YANG, Chaohui Suzhou Jiangsu 215123 (CN) YU, Shu Suzhou Jiangsu 215123 (CN) ZHANG, Xiaoyu Suzhou Jiangsu 215123 (CN) ZHANG, Liang Shanghai 200136 (CN)

(74)	Representative: Grünecker Patent- und Rechtsanwälte PartG mbB
	Leopoldstraße 4 80802 München 80802 München (DE)

(54)	AHU377 CRYSTAL FORM, PREPARATION METHOD AND USE THEREOF

(57) The present disclosure relates to a novel crystalline form of a compound of formula (I), preparation method and use thereof. The novel crystalline form in the present disclosure has good stability, low hygroscopicity, and remarkable purification effect in process. The novel crystalline form of the compound of formula (I) provided by the present disclosure can be used for the preparation of the drug for treating heart failure.